Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

BioVersys Expands Collaboration with GSK and Boosts Series C Funding by CHF 12.3 Million

Wednesday, May 08, 2024

BioVersys AG, a clinical-stage biopharmaceutical company, and GSK plc (LSE/NYSE: GSK), a global biopharma leader, have announced an expansion of their strategic collaboration to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis (TB) treatment.

Alpibectir, a novel small molecule developed through a successful public-private partnership involving GSK, Pasteur Institute Lille, and the University of Lille, is currently undergoing evaluation in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa. This compound, in combination with ethionamide (Eto), introduces a fresh approach to overcoming resistance and enhancing the effectiveness of existing antibiotics.

The collaboration between GSK and BioVersys will extend beyond the current Phase 2a study to develop alpibectir for both pulmonary TB and TB meningitis programs, aiming to make the treatment available to patients expeditiously.

In addition to their collaboration, GSK will make an equity investment in BioVersys’ latest funding round, enhancing the Series C financing by CHF 12.3 million, totaling proceeds of CHF 44.9 million for the Series C round to date. These funds will support the clinical development of BioVersys’ portfolio, including BV100, a potential breakthrough antibiotic targeting Acinetobacter baumannii.

BioVersys, expressed enthusiasm about the expanded collaboration with GSK and the progress in alpibectir's development. He emphasized the urgency in addressing TB, a global health threat with inadequate treatment options.

GSK, highlighted the commitment to combatting TB and the potential of alpibectir to diversify treatment options. He emphasized the importance of partnerships in addressing global health challenges effectively.

TB, caused by Mycobacterium tuberculosis, remains a significant global health concern, with millions of new cases and deaths annually, and a rising incidence of drug-resistant strains. The collaboration between BioVersys and GSK represents a concerted effort to address this pressing public health issue.

 

Source: bioversys.com

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024